Primary Treatment: Statins (Cardiovascular Agents) · No Placebo Group · Phase 4
Evolocumab plus statinExperimental Group · 2 Interventions: Evolocumab, Statins (Cardiovascular Agents) · Intervention Types: Drug, Drug
Experimental Group · 1 Intervention: Evolocumab · Intervention Types: Drug
Drug Approval Stage
How many patients have taken this drug
Statins (Cardiovascular Agents)
Completed Phase 3
Screening: ~3 weeks
Reporting: 12 months
Who is running the clinical trial?
1,291 Previous Clinical Trials
1,306,934 Total Patients Enrolled
Brigham and Women's HospitalLead Sponsor
1,468 Previous Clinical Trials
9,703,534 Total Patients Enrolled
Anil K Chandraker, MDPrincipal InvestigatorBrigham and Women's Hospital
2 Previous Clinical Trials
50 Total Patients Enrolled
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You are aged > 18 years and have a documented ASCVD or diabetes and 1 or more risk factors for ASCVD, including, but not limited to obesity, inactive lifestyle, hypertension, smoking, and family history.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.